Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market - Forecast(2024 - 2030)

Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market Overview

Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market Size is estimated to reach $3.4 billion by 2027 and is poised to grow at a CAGR of 11.4% over the forecast period of 2022-2027. Chronic inflammatory demyelinating polyneuropathy is defined as a neurological disorder in which the immune system attacks myelin which is an important part of the nervous system. It occurs when the immune system of the body is unable to distinguish between a foreign invader and a healthy cell and instead begins to kill healthy cells. Different treatments, including intravenous immunoglobulin, plasmapheresis, physiotherapy and others, are used to treat this disease. Patients with autoimmune diseases are more likely than other patients to get the disease. Medical professionals worldwide are concerned about the rising incidence of CIDP cases, especially in developed countries. Numerous governmental and commercial organizations that have carried out research and development operations and produced advantageous findings have helped the CIDP field. For instance, in February 2021, Pfizer Inc announced that the U.S., Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for PANZYGA to treat adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP). Such inventions and increasing demand for CIPD treatment drive the growth of the Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market over the forecast period 2022-2027.

Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market Report Coverage

The “Chronic Inflammatory Demyelinating Polyneuropathy  Treatment Market Forecast (2022-2027)" by Industry ARC, covers an in-depth analysis of the following segments in the Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market.

Key Takeaways

• Geographically, North America held a dominant market share in the year 2021, owing to the government initiatives to minimize rare diseases and increasing funding for research and developments for new therapeutics, driving Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market size in this region.
• The Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market is predicted to increase owing to the growing prevalence of autoimmune diseases across the world.
• However, the increasing cost of Intravenous Immunoglobulin (IVIG) treatment may limit the Chronic Inflammatory Demyelinating Polyneuropathy  Treatment Industry growth over the forecast period 2022-2027.
• A detailed analysis of strengths, weaknesses, opportunities and threats will be provided in the Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market Report.

Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market Segment Analysis - by Treatment Type

The Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market based on treatment type can be further segmented into Corticosteroids, Intravenous Immunoglobulin Therapy or Immunotherapy, Plasmapheresis or Plasma Exchange Therapy, Physiotherapy and Others. The Intravenous Immunoglobulin (IVIG) Therapy segment held a dominant market share in the year 2021. This is owing to the effectiveness of Intravenous Immunoglobulin Therapy to treat CIPD. The IVIG shows improvements in the symptoms in 3 to 5 days after treatment and it lasts up to 6 weeks. A research review published in the Annals of Blood in March 2021, has shown that IVIg (up to 1 g/kg) is an effective treatment in 70–80% of patients with Immune thrombocytopenia (ITP). Such attributes of Intravenous Immunoglobulin Therapy or Immunotherapy and their increasing demand for treatment of CIPD drive the growth of the Chronic Inflammatory Demyelinating Polyneuropathy  Treatment Market Share.

However, Corticosteroids are estimated to grow with the fastest CAGR of 11.9% over the forecast period 2022-2027. This is owing to the high efficacy for the treatment of CIPD and related diseases. When used alone, corticosteroids like prednisone, prednisolone, dexamethasone and methylprednisolone have proven to be effective. In order to achieve a quick response, they are typically given high dosages every day at first, then gradually decrease to low doses every day to maintain remission. The effectiveness of corticosteroids and their growing demand for treatment of CIPD propel the growth of the Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market Share over the forecast period 2022-2027.

Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market Segment Analysis- by End User

The Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market based on the End User can be further segmented into Hospitals, Specialty Neurological Clinics, Research & Academic Laboratories and Others. The Hospital segment held a dominant market share in the year 2021. There are many illnesses that can lead to chronic inflammatory demyelinating polyradiculoneuropathy, including immunologic and viral conditions. Diagnosis of CIPD is most challenging owing to complications and undiagnosed or over-diagnosed CIPD cases need hospitalization. In 2019, about 30,000 Americans were diagnosed with CIPD. Such an increasing need for hospitalization in CIPD cases drives the growth of the Chronic Inflammatory Demyelinating Polyneuropathy  Treatment Market Share.

However, the Specialty Neurological Clinics segment is estimated to grow with the fastest CAGR of 12.1% over the forecast period 2022-2027. This is owing to the significant role of neurologists in the evolution, diagnosis and treatment of CIPD. The staff at the specialty neurological clinics is composed of a team of specialists who collaborates to provide patients with CIPD with high-quality care and a full recovery. Additionally, CIPD is linked to nodo and paranodopathies, paraproteinemic demyelinating neuropathies (PDN) with and without anti-MAG (Myelin-associated glycoprotein) antibodies and multifocal motor neuropathy (MMN). Such situations require intense care, which is offered by specialist neurological clinics. Such need for specialty neurological clinics for the treatment of CIPD fuels the growth of the Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market Share over the forecast period 2022-2027.

Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market Segment Analysis - by Geography 

North America held a dominant market share of 36% in the year 2021. This is owing to the increasing prevalence of chronic inflammatory demyelinating polyneuropathy. According to the CIPD Foundation International, chronic inflammatory demyelinating polyneuropathy affects about 8.9% per 1,00,000 people every year in North America, which propels the growth of the Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market Size. Furthermore, the Asia-Pacific is estimated to grow with the fastest CAGR of 12.3% over the forecast period 2022-2027. This is owing to the rising prevalence of chronic inflammatory demyelinating polyneuropathy increased investment for research and development and strategic research collaboration between pharmaceutical companies propelling the growth of the Chronic Inflammatory Demyelinating Polyneuropathy Treatment Industry. For instance, the Asia Pacific Society for Immunodeficiencies (APSID) has held nine primary immunodeficiencies (PID) Schools, in the past five years to teach early career physicians in PID care in the Asia Pacific, a region with varying needs for PID resources and education. Also, according to a research paper published in National Center for Biotechnology Information (NCBI) in 2020, about 66 hospitals in Japan are available for diagnosis and management of PIDs. Turkey has two large centers for pediatric immunology in Ankara and Istanbul and two Jeffrey Modell Foundation (JMF) Centers for Immunodeficiencies established in 2020. Such growing awareness about autoimmune diseases in this region fuels the growth of the Chronic Inflammatory Demyelinating Polyneuropathy  Treatment Market Size over the forecast period 2022-2027.

Chronic Inflammatory Demyelinating Polyneuropathy  Treatment Market Drivers

Growing Prevalence of Autoimmune Diseases Drive Market Growth.

The autoimmune disease is rear, but for unknown reasons, the prevalence of autoimmune diseases is increasing. According to the National Institutes for Health (NIH) estimates that autoimmune disease collectively affects between 5% and 8% of the U.S., population. Multiple sclerosis. Myasthenia gravis, Pernicious anemia, Reactive arthritis, Rheumatoid arthritis, Systemic lupus erythematosus and Type I diabetes are the most well-known autoimmune diseases. According to ‘Arthritis Statistics’ by single care, there are about fourteen million people around the world who have rheumatoid arthritis in 2021. Also, as per American Association for Cancer Education (AACE), type 1 diabetes affects about 20 million individuals worldwide. Such a high prevalence of autoimmune diseases drives the growth of the Chronic Inflammatory Demyelinating Polyneuropathy  Treatment Industry over the forecast period 2022-2027.

Growing Research for Development of Novel Treatments Drive Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market Growth.

In autoimmune diseases like Chronic Inflammatory Demyelinating Polyneuropathy, the quality of patient life is extremely low compared to normal healthy people. To minimize the impact of autoimmune disease on quality-of-life various organizations are working to develop better options for available treatments. According to a research paper published in the Research Gate in July 2022, the long-term prognosis of CIDP patients was possible but 39% of patients required immune treatments and 13% had severe disabilities. In July 2022, Wake Forest Institute for Regenerative Medicine (WFIRM) researchers developed a continuous 3,4-DAP infusion model and measured dose-dependent effects on toxic signs and survival after a lethal dose of botulinum neurotoxin. In May 2022, researchers at University College London Great Ormond Street Institute of Child Health (UCL GOS ICH) and Great Ormond Street Hospital (GOSH) received $1,01,592.50 to better understand juvenile dermatomyositis, a rare autoimmune condition and develop better treatments. Such growing research and investment in the development of new drugs and treatments for autoimmune disease fuel the growth of the Chronic Inflammatory Demyelinating Polyneuropathy Treatment Industry over the forecast period 2022-2027.

Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market Challenge

The High Cost of Treatment Hinders the Market Growth.

A rare disorder known as chronic inflammatory demyelinating polyneuropathy (CIDP) typically causes long-term disability. To treat this disease various treatments are used such as corticosteroids, intravenous immunoglobulins (IVIG) and plasma exchange (PLEX). Also, frequent hospital visits and long hospital stay increase the cost of treatment. According to the research paper published in the Taylor & Francis Online in November 2021, the mean medical cost per admission was $4016.62 for treatment of CIPD. Such a high cost of treatment may limit the growth of the Chronic Inflammatory Demyelinating Polyneuropathy  Treatment Industry over the forecast period 2022-2027.

Chronic Inflammatory Demyelinating Polyneuropathy  Treatment Industry Outlook

Product launches, mergers and acquisitions, joint ventures and geographical expansions are key strategies adopted by players in the Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market. The top 10 companies in the Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market are:

1. Bio Products Laboratory Ltd.
2. Janssen Pharmaceutica
3. Grifols
4. Baxter
5. Kedrion S.p.A
6. Octapharma
7. Shire
8. Mitsubishi Tanabe Pharma Corporation
9. CSL Behring
10. Teijin Pharma Limited

Recent Developments

• In June 2022, Bio Products Laboratory (BPL), a leading manufacturer of plasma-derived protein therapies, based in Elstree, UK, announced today the issuance of a marketing authorization for Coagadex in the Dominican Republic. Coagadex is the first and only specific treatment for Hereditary Factor X Deficiency.
• In February 2022, Grifols, one of the world’s leading producers of plasma-derived medicines, announced a collaboration with Endpoint Health, Inc., a precision-medicine therapeutics company dedicated to addressing urgent needs in immune-driven critical care, to develop and commercialize an Antithrombin III (AT-III) therapy to treat Sepsis. 
• In January 2022, Janssen Pharmaceutica announced that they entered into collaboration with SRI International (SRI). Under the terms of the agreement, the organizations and their scientists will leverage SRI's SynFin platform, an artificial intelligence (Al)-guided, automated synthetic- chemistry system for small molecule drug discovery. The agreement was facilitated by Johnson & Johnson Innovation.

Relevant Reports

Autoimmune Disease Therapeutics Market - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth and Forecast Analysis

Report Code: HCR 28103

Physiotherapy & Rehabilitation Products and Services Market - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth and Forecast Analysis

Report Code: HCR 1499

IVIG Market - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth and Forecast Analysis

Report Code: HCR 0233